RxDoctor Payments Data

Jonathan Laymance, MD

Family Medicine · Wartburg, TNNPI 1396058574

Payments from drug & device makers

$958in general payments, 2019–2025

Across 52 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$230
  • AbbVie$190
  • Sanofi$110
  • Phathom Pharmaceuticals, Inc.$82
  • Otsuka America Pharmaceutical, Inc.$37
  • Teva Pharmaceuticals USA, Inc.$35
  • plus $273 from 13 others

What the payments were for

  • Speaking & faculty fees$11011%
  • Food & beverage$84889%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$958 in reported general payments places this provider in the 55th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$144,868
Medicare patients
212
Services billed
5,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$69,933
EliquisApixaban48$62,325
Tresiba Flextouch U-200Insulin Degludec36$62,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$56,054
MounjaroTirzepatide28$38,521
TrulicityDulaglutide17$28,097
Humalog Kwikpen U-200Insulin Lispro17$25,679
XareltoRivaroxaban29$18,004
JardianceEmpagliflozin16$13,712
JanumetSitagliptin Phos/Metformin Hcl17$12,239
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$8,543
Repatha SureclickEvolocumab11$5,873
MyrbetriqMirabegron12$5,211
Levemir FlexpenInsulin Detemir12$4,298
AbrysvoRsv Vacc, Pref A And Pref B/Pf14$3,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$230$69,93341 claims
Lilly USA, LLCMounjaro, Trulicity$20$66,61845 claims
PfizerEliquis, Abrysvo$34$66,25262 claims
GSKTrelegy Ellipta, Shingrix$11$58,42552 claims
Johnson & JohnsonXarelto$13$18,00429 claims
AbbVieSynthroid$190$1,81334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Wartburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →